compound 2-3-2 [PMID: 24900824]   Click here for help

GtoPdb Ligand ID: 8110

Compound class: Synthetic organic
Comment: This BUB1 (BUB1 mitotic checkpoint serine/threonine kinase) inhibitor compound was developed as a potential antineoplastic and was granted patent protection in 2013 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 116.44
Molecular weight 564.23
XLogP 2.54
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOc1cc(F)c(c(c1)F)Cn1nc(c2c1CCC2)c1ncc(c(n1)Nc1ccncc1)OCC1(CO)COC1
Isomeric SMILES CCOc1cc(F)c(c(c1)F)Cn1nc(c2c1CCC2)c1ncc(c(n1)Nc1ccncc1)OCC1(CO)COC1
InChI InChI=1S/C29H30F2N6O4/c1-2-40-19-10-22(30)21(23(31)11-19)13-37-24-5-3-4-20(24)26(36-37)28-33-12-25(41-17-29(14-38)15-39-16-29)27(35-28)34-18-6-8-32-9-7-18/h6-12,38H,2-5,13-17H2,1H3,(H,32,33,34,35)
InChI Key WIVMUEFNJYZIOY-UHFFFAOYSA-N
References
1. Brazeau JF, Rosse G. (2014)
Novel cycloalkenepyrazoles as inhibitors of bub1 kinase.
ACS Med Chem Lett, 5 (4): 280-1. [PMID:24900824]
2. Hitchcock M, Hilger C-S, Mengel A, Briem H, Holton S, P¨:tter V, Siemeister G, Prechtl S, FERNÁNDEZ-MONTALVÁN AE, Stegmann C. (2013)
Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer.
Patent number: WO2013167698. Assignee: Bayer Pharma Aktiengesellschaft. Priority date: 11/05/2012. Publication date: 14/11/2013.